Sankalp Gokhale
Chief Tech/Sci/R&D Officer bij DIANTHUS THERAPEUTICS, INC.
Profiel
Sankalp Gokhale is currently working as the Vice President-Clinical Development at Dianthus Therapeutics, Inc. Prior to this, he held positions as the Medical Director-Clinical Development at Alexion Pharmaceuticals, Inc. and as the Senior Director-Clinical Development at Radius Health, Inc. Dr. Gokhale obtained an MBA from the University of Arizona.
Actieve functies van Sankalp Gokhale
Bedrijven | Functie | Begin |
---|---|---|
DIANTHUS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 11-09-2023 |
Eerdere bekende functies van Sankalp Gokhale
Bedrijven | Functie | Einde |
---|---|---|
ALEXION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
RADIUS HEALTH, INC. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Sankalp Gokhale
University of Arizona | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
DIANTHUS THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Radius Health, Inc.
Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |